SE9103701D0 - Apolipoprotein - Google Patents

Apolipoprotein

Info

Publication number
SE9103701D0
SE9103701D0 SE9103701A SE9103701A SE9103701D0 SE 9103701 D0 SE9103701 D0 SE 9103701D0 SE 9103701 A SE9103701 A SE 9103701A SE 9103701 A SE9103701 A SE 9103701A SE 9103701 D0 SE9103701 D0 SE 9103701D0
Authority
SE
Sweden
Prior art keywords
dimer
pct
apolipoprotein
apo
sec
Prior art date
Application number
SE9103701A
Other languages
English (en)
Swedish (sv)
Inventor
C Sirtori
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Priority to SE9103701A priority Critical patent/SE9103701D0/xx
Publication of SE9103701D0 publication Critical patent/SE9103701D0/xx
Priority to ZA928989A priority patent/ZA928989B/xx
Priority to IL10395692A priority patent/IL103956A/en
Priority to DE69233092T priority patent/DE69233092T2/de
Priority to SK868-93A priority patent/SK86893A3/sk
Priority to EP93900484A priority patent/EP0571602B1/en
Priority to SG1996001800A priority patent/SG47453A1/en
Priority to HU9302344A priority patent/HU217203B/hu
Priority to RO93-01116A priority patent/RO115636B1/ro
Priority to ES93900484T priority patent/ES2199939T3/es
Priority to RU93054168A priority patent/RU2134696C1/ru
Priority to DK93900484T priority patent/DK0571602T3/da
Priority to BR9205640A priority patent/BR9205640A/pt
Priority to NZ246223A priority patent/NZ246223A/en
Priority to PL92314894A priority patent/PL172544B1/pl
Priority to CZ19931589A priority patent/CZ289879B6/cs
Priority to PL92300262A priority patent/PL171907B1/pl
Priority to AU31755/93A priority patent/AU3175593A/en
Priority to MX9207224A priority patent/MX9207224A/es
Priority to CA002103996A priority patent/CA2103996C/en
Priority to PCT/SE1992/000858 priority patent/WO1993012143A1/en
Priority to AT93900484T priority patent/ATE242269T1/de
Priority to PL92314896A priority patent/PL172168B1/pl
Priority to NZ280516A priority patent/NZ280516A/en
Priority to JP5510842A priority patent/JPH07502892A/ja
Priority to PT93900484T priority patent/PT571602E/pt
Priority to US08/104,063 priority patent/US5876968A/en
Priority to BG98036A priority patent/BG61451B1/bg
Priority to NO19932866A priority patent/NO315076B1/no
Priority to FI933557A priority patent/FI115771B/fi
Priority to EE9400375A priority patent/EE03058B1/xx
Priority to HU95P/P00630P priority patent/HU211667A9/hu
Priority to AU59473/96A priority patent/AU703283B2/en
Priority to US09/259,434 priority patent/US6617134B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Ink Jet (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SE9103701A 1991-12-13 1991-12-13 Apolipoprotein SE9103701D0 (sv)

Priority Applications (34)

Application Number Priority Date Filing Date Title
SE9103701A SE9103701D0 (sv) 1991-12-13 1991-12-13 Apolipoprotein
ZA928989A ZA928989B (en) 1991-12-13 1992-11-20 Apolipoprotein.
IL10395692A IL103956A (en) 1991-12-13 1992-12-03 Dimers of apolipoprotein and pharmaceutical compositions containing them
US08/104,063 US5876968A (en) 1991-12-13 1992-12-11 Dimer of molecular variant of apolipoprotein and processes for the production thereof
PL92300262A PL171907B1 (pl) 1991-12-13 1992-12-11 Sposób wytwarzania dimeru Apolipoproteiny AL-Milano PL PL PL
MX9207224A MX9207224A (es) 1991-12-13 1992-12-11 Apolipoproteina.
EP93900484A EP0571602B1 (en) 1991-12-13 1992-12-11 Dimer of molecular variant of apolipoprotein and processes for the production thereof
SG1996001800A SG47453A1 (en) 1991-12-13 1992-12-11 Dimer of molecular variant of apolipoprotein and processes for the production thereof
HU9302344A HU217203B (hu) 1991-12-13 1992-12-11 Apolipoprotein molekuláris variánsának dimerje, és az előállítására szolgáló eljárás
RO93-01116A RO115636B1 (ro) 1991-12-13 1992-12-11 Procedee pentru prepararea dimerului de apolipoproteina ai-milano
ES93900484T ES2199939T3 (es) 1991-12-13 1992-12-11 Dimero de variantes moleculares de apolipoproteina y procedimientos para su produccion.
RU93054168A RU2134696C1 (ru) 1991-12-13 1992-12-11 Димер молекулярного варианта апо-липопротеина, способ его получения и фармацевтическая композиция на его основе
DK93900484T DK0571602T3 (da) 1991-12-13 1992-12-11 Dimer af molekylær variant af apolipoprotein og fremgangsmåder til fremstilling deraf
BR9205640A BR9205640A (pt) 1991-12-13 1992-12-11 Dímero de apolipoproteína ai-milano, composiçao farmacológica, processo de preparaçao do dímero, uso deste na preparaçao de medicamentos e processo para o tratamento de aterosclerose e doenças cardiovasculares
NZ246223A NZ246223A (en) 1991-12-13 1992-12-11 Apolipoprotein a1-milano; compositions
PL92314894A PL172544B1 (pl) 1991-12-13 1992-12-11 Sposób wytwarzania dimeru apolipoproteiny Al-Milano PL PL PL
CZ19931589A CZ289879B6 (cs) 1991-12-13 1992-12-11 Dimerový preparát apolipoproteinu AI-Milano, farmakologický prostředek, způsob výroby dimeru a pouľití
DE69233092T DE69233092T2 (de) 1991-12-13 1992-12-11 Das dimer einer molekularen variant des apolipoproteins und sein herstellungsverfahren
AU31755/93A AU3175593A (en) 1991-12-13 1992-12-11 Dimer of molecular variant of apolipoprotein and processes for the production thereof
SK868-93A SK86893A3 (en) 1991-12-13 1992-12-11 Dimer of molecular variant of apoliprotein and processes for the production thereof
CA002103996A CA2103996C (en) 1991-12-13 1992-12-11 Dimer of molecular variant of apolipoprotein and processes for the production thereof
PCT/SE1992/000858 WO1993012143A1 (en) 1991-12-13 1992-12-11 Dimer of molecular variant of apolipoprotein and processes for the production thereof
AT93900484T ATE242269T1 (de) 1991-12-13 1992-12-11 Das dimer einer molekularen variant des apolipoproteins und sein herstellungsverfahren
PL92314896A PL172168B1 (pl) 1991-12-13 1992-12-11 Sposób wytwarzania dimeru Apolipoproteiny Al-Milano PL PL PL
NZ280516A NZ280516A (en) 1991-12-13 1992-12-11 Treating or preventing cardiovascular disease or athersclerosis using a dimer of apolipoprotein-ai-milano
JP5510842A JPH07502892A (ja) 1991-12-13 1992-12-11 アポリポ蛋白質の分子変異体の２量体およびその製造方法
PT93900484T PT571602E (pt) 1991-12-13 1992-12-11 Alimento medico para diabeticos
BG98036A BG61451B1 (en) 1991-12-13 1993-08-11 Dimer of molecular alternative of apolipoprotein and method for its preparation
NO19932866A NO315076B1 (no) 1991-12-13 1993-08-12 Dimerpreparat av molekyl¶rvariant av apolipoprotein og fremgangsmåter for fremstilling og anvendelse derav, til fremstilling av et medikamentfor behandling av aterosklerose og kardiovaskul¶re sykdommer
FI933557A FI115771B (fi) 1991-12-13 1993-08-12 Menetelmä apolipoproteiinin Al-Milano-dimeerin valmistamiseksi
EE9400375A EE03058B1 (et) 1991-12-13 1994-11-16 Apolipoproteiini molekulaarse teisendi dimeer ja selle valmistamismeetod
HU95P/P00630P HU211667A9 (en) 1991-12-13 1995-06-30 Apolipoprotein
AU59473/96A AU703283B2 (en) 1991-12-13 1996-07-12 Dimer of molecular variant of apolipoprotein and processes for the production thereof
US09/259,434 US6617134B1 (en) 1991-12-13 1999-03-01 Dimer of molecular variant of apolipoprotein and processes for the production thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9103701A SE9103701D0 (sv) 1991-12-13 1991-12-13 Apolipoprotein

Publications (1)

Publication Number Publication Date
SE9103701D0 true SE9103701D0 (sv) 1991-12-13

Family

ID=20384608

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9103701A SE9103701D0 (sv) 1991-12-13 1991-12-13 Apolipoprotein

Country Status (28)

Country Link
US (2) US5876968A (es)
EP (1) EP0571602B1 (es)
JP (1) JPH07502892A (es)
AT (1) ATE242269T1 (es)
AU (2) AU3175593A (es)
BG (1) BG61451B1 (es)
BR (1) BR9205640A (es)
CA (1) CA2103996C (es)
CZ (1) CZ289879B6 (es)
DE (1) DE69233092T2 (es)
DK (1) DK0571602T3 (es)
EE (1) EE03058B1 (es)
ES (1) ES2199939T3 (es)
FI (1) FI115771B (es)
HU (2) HU217203B (es)
IL (1) IL103956A (es)
MX (1) MX9207224A (es)
NO (1) NO315076B1 (es)
NZ (2) NZ246223A (es)
PL (3) PL172168B1 (es)
PT (1) PT571602E (es)
RO (1) RO115636B1 (es)
RU (1) RU2134696C1 (es)
SE (1) SE9103701D0 (es)
SG (1) SG47453A1 (es)
SK (1) SK86893A3 (es)
WO (1) WO1993012143A1 (es)
ZA (1) ZA928989B (es)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9103701D0 (sv) * 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein
SE9203753D0 (sv) * 1992-12-11 1992-12-11 Kabi Pharmacia Ab Expression system for producing apolipoprotein ai-m
SE9500778D0 (sv) * 1995-03-03 1995-03-03 Pharmacia Ab Process for producing a protein
US6258596B1 (en) 1995-05-22 2001-07-10 Aventis Pharmaceuticals Products Inc. Variants of apolipoprotein A-I
FR2734568B1 (fr) * 1995-05-22 1997-06-20 Rhone Poulenc Rorer Sa Nouveaux variants de l'apolipoproteine
SE9603068D0 (sv) * 1996-08-23 1996-08-23 Pharmacia & Upjohn Ab Process for purifying a protein
SE9603304D0 (sv) * 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a compound
SE9603303D0 (sv) 1996-09-11 1996-09-11 Pharmacia & Upjohn Ab Process for purifying a protein
US6306433B1 (en) 1997-08-12 2001-10-23 Pharmacia Ab Method of preparing pharmaceutical compositions
US20020064820A1 (en) * 2000-03-13 2002-05-30 Jean-Michel Dayer Apo-A-I regulation of T-cell signaling
US6743778B2 (en) 2000-04-21 2004-06-01 Amgen Inc. Apo-AI/AII peptide derivatives
BRPI0003386B8 (pt) * 2000-08-08 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda pró-droga homo ou heterodiméricas úteis no tratamento de doenças ou disfunções mediadas por fosfodiesterases; composições farmacêuticas contendo a pró-droga ou seus sais farmacêuticos aceitáveis; processo de obtenção destas pró-drogas
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US6664230B1 (en) * 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
EP1335938B1 (en) * 2000-11-10 2010-09-22 F. Hoffmann-La Roche Ltd. Apolipoprotein construct
US7217785B2 (en) * 2001-05-09 2007-05-15 The Regents Of The University Of California Cysteine-containing peptides having antioxidant properties
WO2003026492A2 (en) * 2001-09-28 2003-04-03 Esperion Therapeutics Inc. Prevention and treatment of restenosis by local administration of drug
US20030229062A1 (en) * 2001-12-07 2003-12-11 The Regents Of The University Of California Treatments for age-related macular degeneration (AMD)
JP2005511713A (ja) * 2001-12-07 2005-04-28 ザ・リージェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア 加齢性黄斑変性についての処置
US7470659B2 (en) * 2001-12-07 2008-12-30 The Regents Of The University Of California Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
US7223726B2 (en) * 2002-01-14 2007-05-29 The Regents Of The University Of California Apolipoprotein A-I mutant proteins having cysteine substitutions and polynucleotides encoding same
US20100204103A1 (en) * 2002-05-08 2010-08-12 The Regents Of The University Of California Helical synthetic peptides that stimulate cellular cholesterol efflux
AU2003239489A1 (en) 2002-05-17 2003-12-02 Esperion Therapeutics, Inc. Method of treating dyslipidemic disorders
PL374126A1 (en) * 2002-05-17 2005-10-03 Esperion Therapeutics, Inc. Methods and copositions for the treatment of ischemic reperfusion
SE0302312D0 (sv) * 2002-10-04 2003-08-27 Forskarpatent I Syd Ab Peptide-based passive immunization therapy for treatment of atherosclerosis
DE10324447A1 (de) 2003-05-28 2004-12-30 Scil Proteins Gmbh Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
PE20050438A1 (es) * 2003-10-20 2005-06-14 Esperion Therapeutics Inc Formulas farmaceuticas, metodos y regimenes de dosificacion para el tratamiento y la prevencion de sindromes coronarios agudos
WO2005051413A2 (en) * 2003-11-26 2005-06-09 Novartis Ag Disease associated genes
EP1706131A4 (en) * 2003-12-15 2009-08-12 Univ California THE CELLULAR CHOLESTEROL EFFLUX STIMULATING HELICULAR SYNTHETIC PEPTIDES
US8926958B2 (en) 2004-04-06 2015-01-06 Cedars-Sinai Medical Center Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein A-I and apolipoprotein A-I milano
KR100560102B1 (ko) * 2004-06-25 2006-03-13 한국생명공학연구원 프로아포리포단백질 ａ－ⅰ 변이체와, 이를 포함하는고지혈증 또는 동맥경화증 예방 및 치료제
US9487575B2 (en) * 2004-07-14 2016-11-08 The Regents Of The University Of California Compositions and methods for treatment of gynecologic cancers
US8206750B2 (en) 2005-03-24 2012-06-26 Cerenis Therapeutics Holding S.A. Charged lipoprotein complexes and their uses
SG173373A1 (en) 2005-04-29 2011-08-29 The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
WO2007000924A1 (ja) * 2005-06-28 2007-01-04 Osaka University プログラニュリン活性を抑制または促進する物質を含む医薬組成物、およびプログラニュリン活性を抑制または促進する物質のスクリーニング方法
KR100719389B1 (ko) 2005-10-18 2007-05-17 주식회사 녹십자 인간혈장으로부터 아포리포단백질 ａ-ｉ을 분리 정제하는방법
US20070254832A1 (en) * 2006-02-17 2007-11-01 Pressler Milton L Methods for the treatment of macular degeneration and related eye conditions
CA2659655A1 (en) 2006-08-08 2008-02-21 Alan M. Fogelman Salicylanilides enhance oral delivery of therapeutic peptides
EP2057270A1 (en) * 2006-08-10 2009-05-13 Plantechno SRL In-plant production of dimeric and/or oligomeric (comprising three or more units) forms of human apo a-1 protein muteins
US8541236B2 (en) * 2006-12-08 2013-09-24 University Of Washington Mutant apolipoprotein A-1 polypeptide with increased resistance to oxidation and reactive carbonyls
JP2010538005A (ja) 2007-08-28 2010-12-09 ユーエービー リサーチ ファウンデーション 合成アポリポ蛋白質ｅ模倣ポリペプチドおよび使用方法
CA2697957A1 (en) 2007-08-28 2009-03-12 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
US20100212030A1 (en) * 2007-10-19 2010-08-19 Pronota N.V. Use of n-terminal and c-terminal proteomics technology to enhance protein therapeutics and diagnostics
JP5600065B2 (ja) 2007-10-23 2014-10-01 ザ クリーブランド クリニック ファウンデーション オキシダント耐性アポリポ蛋白質ａ−１および類似ペプチド
US8241861B1 (en) 2008-07-08 2012-08-14 Insilicos, Llc Methods and compositions for diagnosis or prognosis of cardiovascular disease
CA3029724A1 (en) 2008-11-10 2010-05-14 Muthiah Manoharan Lipids and compositions for the delivery of therapeutics
EP2391343B1 (en) 2009-01-29 2017-03-01 Arbutus Biopharma Corporation Improved lipid formulation for the delivery of nucleic acids
EP2406376A1 (en) 2009-03-12 2012-01-18 Alnylam Pharmaceuticals, Inc. LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES
CA3151387A1 (en) 2009-05-05 2010-11-11 Arbutus Biopharma Corporation Lipid compositions for the delivery of therapeutic agents
NZ712719A (en) 2009-06-10 2017-03-31 Arbutus Biopharma Corp Improved lipid formulation
AP3574A (en) 2009-08-14 2016-02-08 Alnylam Pharmaceuticals Inc Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
US12419839B2 (en) 2009-10-09 2025-09-23 Signablok, Inc. Methods and compositions for targeted delivery of protein fragments
US10894098B2 (en) 2012-04-09 2021-01-19 Signablok, Inc. Methods and compositions for targeted imaging
WO2011044545A2 (en) 2009-10-09 2011-04-14 Sigalov Alexander B Methods and compositions for targeted imaging
AU2010328336B2 (en) 2009-12-07 2017-03-02 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
CN102753569A (zh) * 2009-12-14 2012-10-24 塞尔蛋白质股份有限公司 对纤维连接蛋白额外结构域b具有特异结合活性的修饰的泛素蛋白
EP2512449B1 (en) 2009-12-18 2019-08-07 The University of British Columbia Methods and compositions for delivery of nucleic acids
WO2011139911A2 (en) 2010-04-29 2011-11-10 Isis Pharmaceuticals, Inc. Lipid formulated single stranded rna
WO2011143362A1 (en) * 2010-05-11 2011-11-17 Esperion Therapeutics, Inc. Dimeric oxidation-resistant apolipoprotein a1 variants
NZ605079A (en) 2010-06-03 2015-08-28 Alnylam Pharmaceuticals Inc Biodegradable lipids for the delivery of active agents
WO2012016184A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
US20130202652A1 (en) 2010-07-30 2013-08-08 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
US20130142760A1 (en) 2010-08-18 2013-06-06 Cedars-Sinai Medical Center Atherosclerosis inhibition via modulation of monocyte-macrophage phenotype using apo a-i milano gene transfer
WO2012064824A1 (en) 2010-11-09 2012-05-18 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
JP5902197B2 (ja) 2011-01-11 2016-04-13 アルニラム・ファーマシューティカルズ・インコーポレーテッド Ｐｅｇ化脂質および薬剤送達のためのそれらの使用
DK2673296T3 (en) * 2011-02-07 2019-02-18 Cerenis Therapeutics Holding Sa LIPOPROTEIN COMPLEXES AND PREPARATION AND APPLICATIONS THEREOF
US9492572B2 (en) 2011-06-15 2016-11-15 Scil Proteins Gmbh Dimeric binding proteins based on modified ubiquitins
MX2014001920A (es) 2011-08-25 2014-04-14 Hoffmann La Roche Proteina de fusion acortada de tetranectina-apolipoproteina a-i, una particula lipidica que la contiene, y usos de la misma.
JP6250543B2 (ja) 2011-09-27 2017-12-20 アルニラム・ファーマシューティカルズ・インコーポレーテッド ジ脂肪族置換ｐｅｇ化脂質
US9610324B2 (en) 2012-07-11 2017-04-04 Esperion Therapeutics, Inc. Apolipoprotein mixtures
EP2853259A1 (en) 2013-09-30 2015-04-01 Université Pierre et Marie Curie (Paris 6) Reconstituted high density lipoproteins composition and uses thereof
CA2947127A1 (en) 2014-05-02 2015-11-19 Cerenis Therapeutics Holding Sa Hdl therapy markers
AU2015298263B2 (en) 2014-07-31 2020-05-14 Anji Pharmaceuticals, Inc. ApoE mimetic peptides and higher potency to clear plasma cholesterol
JP6738340B2 (ja) 2015-02-06 2020-08-12 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ 新規なｅｇｆｒ結合タンパク質
ES2916101T3 (es) 2015-07-16 2022-06-28 Navigo Proteins Gmbh Nuevas proteínas de unión a inmunoglobulina y su uso en la purificación por afinidad
US10584152B2 (en) 2015-07-20 2020-03-10 Navigo Proteins Gmbh Binding proteins based on di-ubiquitin muteins and methods for generation
CN109310780A (zh) 2016-05-04 2019-02-05 纳维格蛋白质有限公司 包含肽接头的用于化学部分位点-特异性偶联的靶向化合物
EP3497117B1 (en) 2016-08-11 2024-01-24 Navigo Proteins GmbH Novel alkaline stable immunoglobulin-binding proteins
WO2019030575A1 (en) 2017-08-10 2019-02-14 Cerenis Therapeutics Holding APOMÈRES
WO2019030574A1 (en) 2017-08-10 2019-02-14 Cerenis Therapeutics Holding Cargomers
WO2019091918A1 (en) 2017-11-07 2019-05-16 Navigo Proteins Gmbh Fusion proteins with specificity for ed-b and long serum half-life for diagnosis or treatment of cancer
SG11202105029WA (en) 2018-12-18 2021-06-29 Navigo Proteins Gmbh Novel folr1 specific binding proteins for cancer diagnosis and treatment
AU2021256086A1 (en) 2020-04-16 2022-12-15 Abionyx Pharma Sa Methods for treating acute conditions using lipid binding protein- based complexes
WO2022069942A2 (en) 2020-10-01 2022-04-07 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
WO2022219413A1 (en) 2021-04-15 2022-10-20 Abionyx Pharma Sa Use of lipid binding protein-based complexes in organ preservation solutions
WO2023194797A1 (en) 2022-04-06 2023-10-12 Abionyx Pharma Sa Methods for treating eye diseases using lipid binding protein-based complexes
KR20240171131A (ko) 2022-04-06 2024-12-06 아비오닉스 파마 에스에이 지질 결합 단백질-기반 복합체를 사용하여 백혈구증가증, 내피 기능장애 및 심장염을 치료하는 방법
JP2025519606A (ja) 2022-06-10 2025-06-26 アビオニクス ファーマ エスエー 脂質結合タンパク質に基づく複合体を使用して急性状態を処置するための方法
IL317448A (en) 2022-06-10 2025-02-01 Abionyx Pharma Sa Methods for treating hyperinflammatory conditions using complexes based on lipid-binding proteins
CN121219001A (zh) 2023-01-13 2025-12-26 阿比奥尼克斯制药公司 脂质结合蛋白分子疗法
WO2025093929A1 (en) 2023-10-31 2025-05-08 Abionyx Pharma Sa Lipid binding protein molecule therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8625435D0 (en) * 1986-10-23 1986-11-26 Erba Farmitalia Human apolipoprotein ai
IT1229996B (it) * 1989-04-20 1991-09-20 Cesare Sirtori Espressione di apolipoproteina ai e apolipoproteina ai-milano in lievito e composizioni farmaceutiche che contengono dette apolipoproteine.
SE9103701D0 (sv) * 1991-12-13 1991-12-13 Kabi Pharmacia Ab Apolipoprotein

Also Published As

Publication number Publication date
PT571602E (pt) 2003-10-31
DK0571602T3 (da) 2003-10-06
AU3175593A (en) 1993-07-19
NZ280516A (en) 1997-06-24
JPH07502892A (ja) 1995-03-30
EE03058B1 (et) 1997-12-15
PL171907B1 (pl) 1997-06-30
BG98036A (bg) 1994-05-27
HUT70270A (en) 1995-09-28
WO1993012143A1 (en) 1993-06-24
ATE242269T1 (de) 2003-06-15
BG61451B1 (en) 1997-08-29
DE69233092D1 (de) 2003-07-10
US6617134B1 (en) 2003-09-09
IL103956A0 (en) 1993-05-13
EP0571602A1 (en) 1993-12-01
CZ289879B6 (cs) 2002-04-17
NO932866D0 (no) 1993-08-12
CZ158993A3 (en) 1994-07-13
RO115636B1 (ro) 2000-04-28
HU9302344D0 (en) 1994-01-28
NO315076B1 (no) 2003-07-07
AU5947396A (en) 1996-10-31
ES2199939T3 (es) 2004-03-01
ZA928989B (en) 1993-05-17
CA2103996A1 (en) 1993-06-14
EP0571602B1 (en) 2003-06-04
AU703283B2 (en) 1999-03-25
DE69233092T2 (de) 2004-07-08
FI115771B (fi) 2005-07-15
FI933557A0 (fi) 1993-08-12
RU2134696C1 (ru) 1999-08-20
HU217203B (hu) 1999-12-28
PL172544B1 (pl) 1997-10-31
NO932866L (no) 1993-08-12
IL103956A (en) 1998-09-24
HU211667A9 (en) 1995-12-28
PL172168B1 (pl) 1997-08-29
US5876968A (en) 1999-03-02
BR9205640A (pt) 1994-05-03
PL300262A1 (en) 1994-03-07
CA2103996C (en) 2007-01-16
MX9207224A (es) 1993-06-01
SK86893A3 (en) 1994-04-06
FI933557L (fi) 1993-08-12
NZ246223A (en) 1996-06-25
SG47453A1 (en) 1998-04-17

Similar Documents

Publication Publication Date Title
MX9207224A (es) Apolipoproteina.
RU93054168A (ru) Димер молекулярного варианта аро-липопротеина, способ его получения, фармацевтическая композиция на его основе
NO962664L (no) Forbindelser med veksthormonfrigjörende egenskaper
MY131443A (en) Compounds useful as hypoglycemic agents and for treating alzheimer's disease.
IL126038A0 (en) Novel benzothiepines and derivatives thereof and pharmaceutical compositions comprising them
KR950700333A (ko) 개량된 알파 인터페론 조성물 및 인간 말초혈 백혈구로부터의 제조 방법(improved alpha interferon composition and method for its production from human peripheral blood leukocytes)
CA2040865A1 (en) Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor
ATE412052T1 (de) Synthetische polynukleotide
FI871143A0 (fi) Nya derivater av karboxylsyra, foerfarande foer framstaellning av dessa, deras anvaendning samt laekemedel som innehaoller dessa foereningar.
ATE165514T1 (de) Verwendung von inosittriphosphat zur zubereitung von medikamenten
KR0148213B1 (en) Phenyla lkan(en)oic acid and pharmaceutical composition comprising the same
NZ501492A (en) Di-amine and tetra-amine derivatives and pharmaceuticals thereof, useful for treating cardiac arrhythmia
EP0676197A3 (en) Gammalinolenic acid for the manufacture of a medicament for preventing artery reclosure.
GB9126874D0 (en) Medicaments
DE69213660D1 (de) Verwendung von 1-(beta-d-arabinofuranosyl)-5-propynyluracil zur senkung des serumcholesterins
DK0966455T3 (da) Oxirancarboxylsyrer til behandling af diabetes
ZA954826B (en) New hydrazino and hydroxyamino-14beta-hydroxyandrostane derivatives active on the cardiovascular system processes for their preparation and pharmaceutical compositions containing same
SE9301324D0 (sv) New method of treatment
MX9203171A (es) Composiciones farmaceuticas para el tratamiento de la hipertension arterial.
IT1247508B (it) Composizioni farmaceutiche contenenti l'estere 4-(2 metilamminoetil)- 1,2- fenilenicodell`acido 2-metilpropanoico per il trattamento della neurootticopatia glaucomatosa
IT215302Z2 (it) Tavolo provvisto di porzioni di estremita' sfilabili, disposte inferiormente al suo ripiano e suscettibili di disporsi complanarmente allo stesso.
ITRM910093A1 (it) Procedimento per il trattamento di substrati com composti aromatici contenenti gruppi solfo, composizioni contenenti tali composti e loro preparazione.
DK0868181T3 (da) Anvendelse af alfa,alfa-diphenyleddikesyre-4-(N-methyl-piperidyl)-estere som spasmoanalgetikum